Jorn Drappa
Known title: Chief Medical OfficerCIK: 0001789317
Associated companies
Transaction History
| ALMS | ▼ Sell | Open Market | 2,447 | $65K | 8/3/2026 | View on chart |
| ALMS | ▲ Buy | Option Exercise | 11,317 | $100K | 5/22/2026 | View on chart |
| ALMS | ▲ Buy | Option Exercise | 15,535 | $79K | 5/22/2026 | View on chart |
| ALMS | ▲ Buy | Grant | 25,450 | $0 | 7/29/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Alumis reports positive Phase 3 psoriasis data for envudeucitinib
Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.
Alumis reports positive Phase 3 psoriasis data for envudeucitinib. Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.